Open full discussion button- placeholder 3
Case Discussion · Bilateral Hip OA
Two hips, one patient, two different conversations
A 50-year-old physically active woman presents with bilateral hip osteoarthritis — severe on the left, mild on the right. The left hip is, by current evidence, beyond the IL-333 window. The right hip is squarely inside it. The clinical question is no longer “Is she a candidate?” but “Which side, and when?”
Patient summary
50-year-old woman, physically active (recreational sport). Pain in the left hip for 4–5 years, predominantly weight-bearing, intensifying over recent months. Positive FABER on the left. Pelvic radiograph: severe joint-space narrowing, subchondral sclerosis, and osteophytosis on the left; minimal joint-space narrowing with early osteophyte formation on the right. No symptoms reported on the right side at presentation.
This is the conversation that, until very recently, did not exist in osteoarthritis. Patients were assessed as a single composite — symptoms, function, radiographic severity — and triaged toward analgesia, physiotherapy, weight management, and eventually surgery. Each hip was not separately a therapeutic target. With a candidate disease-modifier in the picture, the joint-by-joint logic changes. Left and right hip become two clinical problems, requiring two distinct decisions.
The two-hip framework
The IL-333 hypothesis, briefly: selective neutralization of cartilage-resident IL-333 preserves chondrocyte populations and slows — sometimes reverses — early structural change. The therapeutic effect is most pronounced where there is still cartilage to protect. In preclinical and exploratory clinical work, the signal is concentrated in Kellgren-Lawrence grade 1–2, attenuated in KL 3, and absent in KL 4. This is a therapy of opportunity, not of rescue.
For this patient, that translates directly:
The left hip shows the radiographic and clinical picture of advanced disease: substantial joint-space loss, subchondral sclerosis, well-formed osteophytes, and a positive FABER with weight-bearing pain that is progressing. By the time cartilage thickness drops below the threshold seen in KL 3–4, IL-333 blockade does not have a chondrocyte population large enough to protect. There is nothing for the drug to preserve.
Several years ago — at presentation, when symptoms were beginning and the radiograph almost certainly showed earlier-stage change — this hip would likely have been a strong candidate. That window has closed.
The right hip is the more interesting clinical problem. Radiographically, it sits at KL 1–2: minimal joint-space narrowing, subtle subchondral changes, early osteophyte formation. Symptomatically, it is currently quiet. This is precisely the configuration in which IL-333 blockade has shown its largest effect in early data — preservation of cartilage thickness and, in a subset of patients, modest gain.
The patient’s age (50), physical activity, and the contralateral severe disease together make her natural history on the right side relatively predictable: progression is the expected trajectory. The question is whether to intervene before symptoms drive the decision.
Eligibility, criterion-by-criterion
The BPM-OA-201 protocol screens both clinical and biological eligibility. Mapping this patient’s two hips against the published inclusion and exclusion criteria — independently — produces a clean illustration of why one side is a candidate and the other is not.
Left hip NOT ELIGIBLE
Inclusion criterion 1.1
Right hip CANDIDATE
Inclusion criterion 1.1
Why “now” matters more than “wait and see”
One reasonable counter-argument deserves direct attention: “The right hip is asymptomatic. Why intervene?” The standard answer — wait until symptoms drive the decision — was clinically defensible when no disease-modifying option existed. With a candidate that is most effective in KL 1–2 and loses effect by KL 3, waiting becomes its own decision. Each year of natural progression that takes a hip from KL 2 to KL 3 is, on the IL-333 hypothesis, a year in which the available therapeutic effect is shrinking. If the trial signal holds, the cost of waiting is not just delayed benefit; it is loss of the eligibility window itself.
That logic is, of course, contingent on the trial reading out positively. But for a 50-year-old patient with a contralateral hip already at KL 4 — a proxy for her individual susceptibility to OA progression — the prior probability of progression on the right side is high enough that screening into a structured trial is a reasonable path to discuss. The alternative is the same path the left hip took.
Practical next steps
Three concrete actions follow from this analysis:
Discussion takeaways
- Treat each hip as its own clinical decision. In disease-modification-era OA, the left and right hip can require entirely different pathways within the same patient visit. Composite assessments obscure this.
- Left hip → standard-of-care and surgical evaluation pathway. Symptom management, weight-bearing modification, surgical timing per patient preference. IL-333 trial enrollment is not appropriate; the structural reserve is gone.
- Right hip → trial-screening conversation. Refer for BPM-OA-201 evaluation: qMRI cartilage thickness, synovial-fluid or serum IL-333 ELISA, formal KL grading. The right hip is the case where waiting has a measurable cost.
- Counsel on the asymmetric trajectory. The patient should understand why two different recommendations arise from one consultation — particularly because the most active intervention is being proposed for the side that is currently asymptomatic.
- Document the window framework. Whether or not the patient enters BPM-OA-201, the right-hip decision will recur in 12, 24, 36 months. A documented baseline (qMRI, IL-333 level, symptoms) makes the subsequent conversation tractable.
For this patient · BPM-OA-201
Refer the right hip for screening, or locate the nearest participating site
BPM-OA-201 is currently enrolling KL 1–2 hip OA across 22 sites in the US and EU. Site investigators handle screening qMRI and IL-333 ELISA. Patients are not enrolled by their primary clinician — only referred.
Site list & referral form
Clinician discussion
3 comments · open to verified clinicians · moderated
Comments are reviewed before posting. By submitting, you agree to the platform’s clinician code of conduct. This is a sales-demonstration page — comments are not stored.
The asymmetric framing is the right one and probably under-discussed. My hesitation is purely on the right-hip side: the strongest argument for screening is the contralateral KL 4, which functions as a probabilistic statement about her trajectory. If we are willing to make decisions based on that, we should at least acknowledge we are doing so — and document it. Counseling will need to be careful.
From the surgical side, I think the left hip pathway is straightforward: she’s not at the OR door yet, but she is on that road. The interesting question, frankly, is the one this discussion raises — whether the trial conversation for the right hip changes my pre-op counseling for the left. If the right hip is enrolled and stabilized, my downstream load planning is different than if we expect her to need a second arthroplasty in 7–10 years.
Practical question for whoever has experience referring into BPM-OA-201: how heavy is the screening visit for an asymptomatic patient? My concern is that a 50-year-old with a busy life will not come back for a qMRI plus an arthrocentesis when nothing currently hurts. The window logic is real but the patient-experience logic is also real, and they are pulling in different directions.